

Alan G Ramsay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2610869/publications.pdf>

Version: 2024-02-01

79
papers

4,236
citations

186209

28
h-index

114418

63
g-index

80
all docs

80
docs citations

80
times ranked

6002
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurse-like cell co-cultures. <i>Leukemia</i> , 2022, 36, 1324-1335.	3.3	9
2	Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7874.	1.8	2
3	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	0.6	40
4	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 626818.	1.3	13
5	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627020.	2.2	11
6	ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. <i>ELife</i> , 2021, 10, .	2.8	11
7	Targeting the tumor microenvironment in chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2312-2324.	1.7	41
8	Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma. <i>Leukemia</i> , 2021, 35, 3581-3584.	3.3	13
9	Immunomodulatory Drugs for the Treatment of B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8572.	1.8	22
10	The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy. <i>Blood</i> , 2021, 138, 3718-3718.	0.6	2
11	Differential Effects of Ibrdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing. <i>Blood</i> , 2021, 138, 718-718.	0.6	1
12	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 ^{int} TCF-1 ⁺ CD8 ⁺ T _H cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
13	T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. <i>Clinical Cancer Research</i> , 2020, 26, 4958-4969.	3.2	18
14	Combination lenalidomide+rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 240-253.	1.2	39
15	miR-181c -BRK1 axis plays a key role in actin cytoskeleton-dependent T cell function. <i>Journal of Leukocyte Biology</i> , 2018, 103, 855-866.	1.5	8
16	Combination targeted therapy in chronic lymphocytic leukaemia " can pre-clinical studies translate to the clinic?. <i>British Journal of Haematology</i> , 2018, 182, 315-316.	1.2	0
17	Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling. <i>Blood</i> , 2018, 132, 237-237.	0.6	2
18	Diffuse Large B-Cell Lymphoma Remodels the Fibroblastic Reticular Network That Acquires Aberrant Immunosuppressive Capabilities; Implications for the Regulation of Anti-Tumor Immunity in the Immuno-Oncology Era. <i>Blood</i> , 2018, 132, 675-675.	0.6	10

#	ARTICLE	IF	CITATIONS
19	Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial. <i>Blood</i> , 2018, 132, 236-236.	0.6	7
20	Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies. <i>Blood</i> , 2018, 132, 4400-4400.	0.6	0
21	Activity of lenalidomide in mantle cell lymphoma can be explained by <sc>NK</sc> cell-mediated cytotoxicity. <i>British Journal of Haematology</i> , 2017, 179, 399-409.	1.2	39
22	Nurse-like cells impact on disease progression in chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2016, 6, e381-e381.	2.8	26
23	Extracellular vesicles released by CD40/IL-4-stimulated CLL cells confer altered functional properties to CD4+ T cells. <i>Blood</i> , 2016, 128, 542-552.	0.6	48
24	Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumour microenvironment. <i>British Journal of Haematology</i> , 2016, 172, 7-8.	1.2	2
25	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , 2016, 128, 563-573.	0.6	27
26	Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 471-482.	1.9	89
27	Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1. <i>Blood</i> , 2016, 128, 132-132.	0.6	1
28	Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC α subversion induces up-regulation of PKC β expression in B lymphocytes. <i>Haematologica</i> , 2015, 100, 499-510.	1.7	8
29	Exosomes and CAFs: partners in crime. <i>Blood</i> , 2015, 126, 1053-1055.	0.6	5
30	Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege. <i>Blood</i> , 2015, 126, 1474-1474.	0.6	2
31	Targeting the Immune Checkpoint Network in Lymphoid Malignancy. <i>Blood</i> , 2015, 126, SCI-47-SCI-47.	0.6	1
32	CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse. <i>Blood</i> , 2015, 126, 1738-1738.	0.6	1
33	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , 2014, 123, 4101-4110.	0.6	63
34	How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. <i>Blood</i> , 2014, 124, 2184-2189.	0.6	60
35	Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2013, 145, 1121-1132.	0.6	439
36	Immune checkpoint blockade immunotherapy to activate anti-tumour <sc>T</sc>-cell immunity. <i>British Journal of Haematology</i> , 2013, 162, 313-325.	1.2	102

#	ARTICLE	IF	CITATIONS
37	Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation. <i>Journal of Clinical Oncology</i> , 2013, 31, 2654-2661.	0.8	101
38	Chronic lymphocytic leukemia cells induce defective LFA-1â€‘directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. <i>Blood</i> , 2013, 121, 2704-2714.	0.6	116
39	T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. <i>Blood</i> , 2013, 121, 1612-1621.	0.6	422
40	Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2013, 121, 4137-4141.	0.6	79
41	Identifying CLL antigens for future combinational therapy. <i>Blood</i> , 2013, 122, 3241-3242.	0.6	1
42	NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide. <i>Blood</i> , 2013, 122, 4131-4131.	0.6	1
43	Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility. <i>Blood</i> , 2013, 122, 4159-4159.	0.6	0
44	Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3389-3398.	0.9	19
45	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. <i>Blood</i> , 2012, 120, 1412-1421.	0.6	320
46	Immune Reconstitution in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 13-20.	1.2	23
47	Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide. <i>Blood</i> , 2012, 120, 564-564.	0.6	0
48	Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On EÎ¼4-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo. <i>Blood</i> , 2012, 120, 313-313.	0.6	1
49	The kiss of death in FL. <i>Blood</i> , 2011, 118, 5365-5366.	0.6	3
50	Psoriasin (S100A7) associates with integrin Î²6 subunit and is required for Î±VÎ²6-dependent carcinoma cell invasion. <i>Oncogene</i> , 2011, 30, 1422-1435.	2.6	30
51	Chronic Lymphocytic Leukemia: An Update on Biology and Treatment. <i>Current Oncology Reports</i> , 2011, 13, 379-85.	1.8	15
52	Substrate-driven gene expression in <i>Roseburia inulinivorans</i> : Importance of inducible enzymes in the utilization of inulin and starch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4672-4679.	3.3	119
53	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1794-1794.	0.6	2
54	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 246-246.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 976-976.	0.6	2
56	T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus. <i>Blood</i> , 2011, 118, 1780-1780.	0.6	0
57	Chronic Lymphocytic Leukemia Cells Co-Opt CD200, CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse. <i>Blood</i> , 2011, 118, 802-802.	0.6	0
58	Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. <i>Journal of Immunotherapy</i> , 2010, 33, 684-696.	1.2	58
59	Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. <i>Blood</i> , 2010, 115, 5053-5056.	0.6	113
60	The 3 Rs in CLL immune dysfunction. <i>Blood</i> , 2010, 115, 2563-2564.	0.6	3
61	T-cell function in chronic lymphocytic leukaemia. <i>Seminars in Cancer Biology</i> , 2010, 20, 431-438.	4.3	44
62	Defective LFA-1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway. <i>Blood</i> , 2010, 116, 914-914.	0.6	0
63	Functional Screening Studies Identify Combinational Activity of PD-L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 696-696.	0.6	0
64	Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients with Follicular Lymphoma at Diagnosis. <i>Blood</i> , 2010, 116, 141-141.	0.6	2
65	E $\frac{1}{4}$ - <i>TCL1</i> mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6250-6255.	3.3	112
66	Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. <i>Blood</i> , 2009, 114, 3909-3916.	0.6	190
67	Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. <i>Blood</i> , 2009, 114, 4713-4720.	0.6	215
68	Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. <i>Haematologica</i> , 2009, 94, 1198-1202.	1.7	56
69	Vaccine therapy and chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 421-436.	0.7	8
70	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. <i>Journal of Clinical Investigation</i> , 2008, 118, 2427-37.	3.9	487
71	Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in Follicular Lymphoma. <i>Blood</i> , 2008, 112, 885-885.	0.6	1
72	Defective T Cell Migration in Chronic Lymphocytic Leukemia Is Repaired by Lenalidomide. <i>Blood</i> , 2008, 112, 3117-3117.	0.6	0

#	ARTICLE	IF	CITATIONS
73	A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction. <i>Blood</i> , 2008, 112, 30-30.	0.6	0
74	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2905-2905.	0.6	0
75	HS1-Associated Protein X-1 Regulates Carcinoma Cell Migration and Invasion via Clathrin-Mediated Endocytosis of Integrin $\alpha 6$. <i>Cancer Research</i> , 2007, 67, 5275-5284.	0.4	127
76	Integrin trafficking and its role in cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 567-78.	2.7	112
77	Impaired Actin Polymerization Results in Defective Immunological Synapse Formation in T Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2007, 110, 338-338.	0.6	2
78	Cell-associated α -amylases of butyrate-producing Firmicute bacteria from the human colon. <i>Microbiology (United Kingdom)</i> , 2006, 152, 3281-3290.	0.7	81
79	Effects of Alternative Dietary Substrates on Competition between Human Colonic Bacteria in an Anaerobic Fermentor System. <i>Applied and Environmental Microbiology</i> , 2003, 69, 1136-1142.	1.4	151